Comparison of Plasma Metabolites From Patients With Non-Small Cell Lung Cancer by Erlotinib Treatment and Skin Rash
Erlotinib is a necessary anticancer treatment for non-small cell lung cancer (NSCLC) patients yet it causes severe side effects such as skin rash. In this study, researchers compared the untargeted compound profiles before and after erlotinib administration to observe changes in blood metabolites in...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2023-09-01
|
| Series: | Integrative Cancer Therapies |
| Online Access: | https://doi.org/10.1177/15347354231198090 |
| _version_ | 1797673052104818688 |
|---|---|
| author | Won Kil Lee PhD Jisoo Myong KMD, PhD Eunbin Kwag MS Younmin Shin MS Ji Woong Son MD, PhD Byong Chul Yoo PhD Byoung-Soo Kim KMD, PhD Hwa-Seung Yoo KMD, PhD Jeong June Choi PhD |
| author_facet | Won Kil Lee PhD Jisoo Myong KMD, PhD Eunbin Kwag MS Younmin Shin MS Ji Woong Son MD, PhD Byong Chul Yoo PhD Byoung-Soo Kim KMD, PhD Hwa-Seung Yoo KMD, PhD Jeong June Choi PhD |
| author_sort | Won Kil Lee PhD |
| collection | DOAJ |
| description | Erlotinib is a necessary anticancer treatment for non-small cell lung cancer (NSCLC) patients yet it causes severe side effects such as skin rash. In this study, researchers compared the untargeted compound profiles before and after erlotinib administration to observe changes in blood metabolites in NSCLC patients. The levels of 1005 substances changed after taking erlotinib. The levels of 306 and 699 metabolites were found to have increased and decreased, respectively. We found 5539 substances with peak area differences based on the presence of skin rash. Carbohydrate, amino acid, and vitamin metabolic pathways were altered in response to the onset of erlotinib-induced skin rash. Finally, this study proposed using plasma metabolites to identify biomarker(s) induced by erlotinib, as well as target molecule(s), for the treatment of dermatological toxic effects. |
| first_indexed | 2024-03-11T21:38:53Z |
| format | Article |
| id | doaj.art-8f3cc2b6fadb44439a72437d6bdb0a45 |
| institution | Directory Open Access Journal |
| issn | 1552-695X |
| language | English |
| last_indexed | 2024-03-11T21:38:53Z |
| publishDate | 2023-09-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Integrative Cancer Therapies |
| spelling | doaj.art-8f3cc2b6fadb44439a72437d6bdb0a452023-09-26T13:33:25ZengSAGE PublishingIntegrative Cancer Therapies1552-695X2023-09-012210.1177/15347354231198090Comparison of Plasma Metabolites From Patients With Non-Small Cell Lung Cancer by Erlotinib Treatment and Skin RashWon Kil Lee PhD0Jisoo Myong KMD, PhD1Eunbin Kwag MS2Younmin Shin MS3Ji Woong Son MD, PhD4Byong Chul Yoo PhD5Byoung-Soo Kim KMD, PhD6Hwa-Seung Yoo KMD, PhD7Jeong June Choi PhD8Daejeon University, Daejeon, Republic of KoreaDaejeon University, Seoul, Republic of KoreaDaejeon University, Daejeon, Republic of KoreaDaejeon University, Daejeon, Republic of KoreaKonyang University Hospital, Daejeon, Republic of KoreaInnoBation Bio, Seoul, Republic of KoreaDaejeon University, Daejeon, Republic of KoreaDaejeon University, Seoul, Republic of KoreaDaejeon University, Daejeon, Republic of KoreaErlotinib is a necessary anticancer treatment for non-small cell lung cancer (NSCLC) patients yet it causes severe side effects such as skin rash. In this study, researchers compared the untargeted compound profiles before and after erlotinib administration to observe changes in blood metabolites in NSCLC patients. The levels of 1005 substances changed after taking erlotinib. The levels of 306 and 699 metabolites were found to have increased and decreased, respectively. We found 5539 substances with peak area differences based on the presence of skin rash. Carbohydrate, amino acid, and vitamin metabolic pathways were altered in response to the onset of erlotinib-induced skin rash. Finally, this study proposed using plasma metabolites to identify biomarker(s) induced by erlotinib, as well as target molecule(s), for the treatment of dermatological toxic effects.https://doi.org/10.1177/15347354231198090 |
| spellingShingle | Won Kil Lee PhD Jisoo Myong KMD, PhD Eunbin Kwag MS Younmin Shin MS Ji Woong Son MD, PhD Byong Chul Yoo PhD Byoung-Soo Kim KMD, PhD Hwa-Seung Yoo KMD, PhD Jeong June Choi PhD Comparison of Plasma Metabolites From Patients With Non-Small Cell Lung Cancer by Erlotinib Treatment and Skin Rash Integrative Cancer Therapies |
| title | Comparison of Plasma Metabolites From Patients With Non-Small Cell Lung Cancer by Erlotinib Treatment and Skin Rash |
| title_full | Comparison of Plasma Metabolites From Patients With Non-Small Cell Lung Cancer by Erlotinib Treatment and Skin Rash |
| title_fullStr | Comparison of Plasma Metabolites From Patients With Non-Small Cell Lung Cancer by Erlotinib Treatment and Skin Rash |
| title_full_unstemmed | Comparison of Plasma Metabolites From Patients With Non-Small Cell Lung Cancer by Erlotinib Treatment and Skin Rash |
| title_short | Comparison of Plasma Metabolites From Patients With Non-Small Cell Lung Cancer by Erlotinib Treatment and Skin Rash |
| title_sort | comparison of plasma metabolites from patients with non small cell lung cancer by erlotinib treatment and skin rash |
| url | https://doi.org/10.1177/15347354231198090 |
| work_keys_str_mv | AT wonkilleephd comparisonofplasmametabolitesfrompatientswithnonsmallcelllungcancerbyerlotinibtreatmentandskinrash AT jisoomyongkmdphd comparisonofplasmametabolitesfrompatientswithnonsmallcelllungcancerbyerlotinibtreatmentandskinrash AT eunbinkwagms comparisonofplasmametabolitesfrompatientswithnonsmallcelllungcancerbyerlotinibtreatmentandskinrash AT younminshinms comparisonofplasmametabolitesfrompatientswithnonsmallcelllungcancerbyerlotinibtreatmentandskinrash AT jiwoongsonmdphd comparisonofplasmametabolitesfrompatientswithnonsmallcelllungcancerbyerlotinibtreatmentandskinrash AT byongchulyoophd comparisonofplasmametabolitesfrompatientswithnonsmallcelllungcancerbyerlotinibtreatmentandskinrash AT byoungsookimkmdphd comparisonofplasmametabolitesfrompatientswithnonsmallcelllungcancerbyerlotinibtreatmentandskinrash AT hwaseungyookmdphd comparisonofplasmametabolitesfrompatientswithnonsmallcelllungcancerbyerlotinibtreatmentandskinrash AT jeongjunechoiphd comparisonofplasmametabolitesfrompatientswithnonsmallcelllungcancerbyerlotinibtreatmentandskinrash |